These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 14550771)
1. Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity. Wersinger C; Prou D; Vernier P; Niznik HB; Sidhu A Mol Cell Neurosci; 2003 Sep; 24(1):91-105. PubMed ID: 14550771 [TBL] [Abstract][Full Text] [Related]
2. Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant. Wersinger C; Vernier P; Sidhu A Biochemistry; 2004 Feb; 43(5):1242-53. PubMed ID: 14756560 [TBL] [Abstract][Full Text] [Related]
3. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine. Moussa CE; Wersinger C; Tomita Y; Sidhu A Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920 [TBL] [Abstract][Full Text] [Related]
4. Attenuation of dopamine transporter activity by alpha-synuclein. Wersinger C; Sidhu A Neurosci Lett; 2003 Apr; 340(3):189-92. PubMed ID: 12672538 [TBL] [Abstract][Full Text] [Related]
5. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease. Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146 [TBL] [Abstract][Full Text] [Related]
6. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148 [TBL] [Abstract][Full Text] [Related]
7. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. Lee FJ; Liu F; Pristupa ZB; Niznik HB FASEB J; 2001 Apr; 15(6):916-26. PubMed ID: 11292651 [TBL] [Abstract][Full Text] [Related]
8. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Junn E; Mouradian MM Neurosci Lett; 2002 Mar; 320(3):146-50. PubMed ID: 11852183 [TBL] [Abstract][Full Text] [Related]
9. Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro. Lehmensiek V; Tan EM; Schwarz J; Storch A Neuroreport; 2002 Jul; 13(10):1279-83. PubMed ID: 12151787 [TBL] [Abstract][Full Text] [Related]
10. Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with alpha-synuclein and its familial Parkinson's disease-linked mutants. Wersinger C; Sidhu A Neurosci Lett; 2003 May; 342(1-2):124-8. PubMed ID: 12727333 [TBL] [Abstract][Full Text] [Related]
11. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. Wersinger C; Prou D; Vernier P; Sidhu A FASEB J; 2003 Nov; 17(14):2151-3. PubMed ID: 12958153 [TBL] [Abstract][Full Text] [Related]
12. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Li J; Uversky VN; Fink AL Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511 [TBL] [Abstract][Full Text] [Related]
13. Structures and free energy landscapes of the wild-type and A30P mutant-type α-synuclein proteins with dynamics. Wise-Scira O; Aloglu AK; Dunn A; Sakallioglu IT; Coskuner O ACS Chem Neurosci; 2013 Mar; 4(3):486-97. PubMed ID: 23374072 [TBL] [Abstract][Full Text] [Related]
14. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Volles MJ; Lansbury PT Biochemistry; 2002 Apr; 41(14):4595-602. PubMed ID: 11926821 [TBL] [Abstract][Full Text] [Related]
15. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70. Albani D; Peverelli E; Rametta R; Batelli S; Veschini L; Negro A; Forloni G FASEB J; 2004 Nov; 18(14):1713-5. PubMed ID: 15345691 [TBL] [Abstract][Full Text] [Related]
16. alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Sharon R; Goldberg MS; Bar-Josef I; Betensky RA; Shen J; Selkoe DJ Proc Natl Acad Sci U S A; 2001 Jul; 98(16):9110-5. PubMed ID: 11481478 [TBL] [Abstract][Full Text] [Related]
17. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein. Bussell R; Eliezer D Biochemistry; 2004 Apr; 43(16):4810-8. PubMed ID: 15096050 [TBL] [Abstract][Full Text] [Related]
18. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease. Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676 [TBL] [Abstract][Full Text] [Related]
19. Fe(II)-induced DNA damage in alpha-synuclein-transfected human dopaminergic BE(2)-M17 neuroblastoma cells: detection by the Comet assay. Martin FL; Williamson SJ; Paleologou KE; Hewitt R; El-Agnaf OM; Allsop D J Neurochem; 2003 Nov; 87(3):620-30. PubMed ID: 14535945 [TBL] [Abstract][Full Text] [Related]
20. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. Choi W; Zibaee S; Jakes R; Serpell LC; Davletov B; Crowther RA; Goedert M FEBS Lett; 2004 Oct; 576(3):363-8. PubMed ID: 15498564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]